[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "PHARMAC received an application to fund Viekira Pak for all its indications.",
          "fs": "PHARMAC received an application to fund Viekira Pak for all its indications.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2015",
          "fs": "May 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA14UAG"
          },
          "Id": "a0P2P000005PA14UAG",
          "Event_Date__c": "2015-05-27",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Summary__c": "PHARMAC received an application to fund Viekira Pak for all its indications.",
          "Formatted_Date__c": "May 2015",
          "Status_History__c": "a132P000000Aqw7QAC"
        },
        "change": null
      }
    ],
    "dateString": "May 2015",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2015",
          "fs": "Aug 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA15UAG"
          },
          "Id": "a0P2P000005PA15UAG",
          "Event_Date__c": "2015-08-13",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Aug 2015",
          "Status_History__c": "a132P000000AqxZQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Committee recommended that paritaprevir/ritonavir, ombitasvir, dasabuvir +/-  ribavirin (PROD) should be funded for the treatment of chronic hepatitis C genotype 1  infection in adults with a low priority based solely on fiscal risk.",
          "fs": "The Committee recommended that paritaprevir/ritonavir, ombitasvir, dasabuvir +/-  ribavirin (PROD) should be funded for the treatment of chronic hepatitis C genotype 1  infection in adults with a low priority based solely on fiscal risk.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Low",
          "fs": "Low",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2015",
          "fs": "Aug 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA16UAG"
          },
          "Id": "a0P2P000005PA16UAG",
          "Event_Date__c": "2015-08-13",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Low",
          "Summary__c": "The Committee recommended that paritaprevir/ritonavir, ombitasvir, dasabuvir +/-  ribavirin (PROD) should be funded for the treatment of chronic hepatitis C genotype 1  infection in adults with a low priority based solely on fiscal risk.",
          "Formatted_Date__c": "Aug 2015",
          "Status_History__c": "a132P000000AqxmQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Low",
          "fs": "Low",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2016",
          "fs": "Feb 2016",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA19UAG"
          },
          "Id": "a0P2P000005PA19UAG",
          "Event_Date__c": "2016-02-11",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "Low",
          "Formatted_Date__c": "Feb 2016",
          "Status_History__c": "a132P000000Ar4nQAC"
        },
        "change": null
      }
    ],
    "dateString": "Aug 2015",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2015",
          "fs": "Aug 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA17UAG"
          },
          "Id": "a0P2P000005PA17UAG",
          "Event_Date__c": "2015-08-14",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Aug 2015",
          "Status_History__c": "a132P000000AqyYQAS"
        },
        "change": null
      }
    ],
    "dateString": "Aug 2015",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2015",
          "fs": "Sep 2015",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA18UAG"
          },
          "Id": "a0P2P000005PA18UAG",
          "Event_Date__c": "2015-09-01",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Sep 2015",
          "Status_History__c": "a132P000000AqzKQAS"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2015",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2016",
          "fs": "May 2016",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA1AUAW"
          },
          "Id": "a0P2P000005PA1AUAW",
          "Event_Date__c": "2016-05-04",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Formatted_Date__c": "May 2016",
          "Status_History__c": "a132P000000Ar7KQAS"
        },
        "change": null
      }
    ],
    "dateString": "May 2016",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "This proposal would see paritaprevir, ritonavir and ombitasvir with dasabuvir, with and without ribavirin (Viekira Pak and Viekira Pak-RBV) funded from 1 July 2016 without restriction (noting that Viekira Pak is only suitable for the genotype 1 virus).     The consultation also looks at providing another treatment for high-need patients regardless of genotype. See other applications for more details.",
          "fs": "This proposal would see paritaprevir, ritonavir and ombitasvir with dasabuvir, with and without ribavirin (Viekira Pak and Viekira Pak-RBV) funded from 1 July 2016 without restriction (noting that Viekira Pak is only suitable for the genotype 1 virus).     The consultation also looks at providing another treatment for high-need patients regardless of genotype. See other applications for more details.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2016",
          "fs": "May 2016",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA1BUAW"
          },
          "Id": "a0P2P000005PA1BUAW",
          "Event_Date__c": "2016-05-25",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Summary__c": "This proposal would see paritaprevir, ritonavir and ombitasvir with dasabuvir, with and without ribavirin (Viekira Pak and Viekira Pak-RBV) funded from 1 July 2016 without restriction (noting that Viekira Pak is only suitable for the genotype 1 virus).     The consultation also looks at providing another treatment for high-need patients regardless of genotype. See other applications for more details.",
          "Formatted_Date__c": "May 2016",
          "Status_History__c": "a132P000000Ar8wQAC"
        },
        "change": null
      }
    ],
    "dateString": "May 2016",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": "From 1 July 2016 Viekira Pak and Viekira Pak-RBV will be funded in the community and DHB hospitals for the treatment of genotype 1 non advanced hepatitis C with a prescriber restriction limiting access to infectious disease specialists, gastroenterologists and hepatologists.    This prescriber restriction will be lifted on 1 October 2016, meaning that any relevant prescriber will be able to access full funding for those products from that date",
          "fs": "From 1 July 2016 Viekira Pak and Viekira Pak-RBV will be funded in the community and DHB hospitals for the treatment of genotype 1 non advanced hepatitis C with a prescriber restriction limiting access to infectious disease specialists, gastroenterologists and hepatologists.    This prescriber restriction will be lifted on 1 October 2016, meaning that any relevant prescriber will be able to access full funding for those products from that date",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/news/notification-2016-06-10-hepatitis-c-treatments/\" target=\"_blank\">Notification letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/news/notification-2016-06-10-hepatitis-c-treatments/\" target=\"_blank\">Notification letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2016",
          "fs": "Jun 2016",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been approved.",
          "fs": "The funding application has been approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA1CUAW"
          },
          "Id": "a0P2P000005PA1CUAW",
          "Event_Date__c": "2016-06-08",
          "Event_Description__c": "The funding application has been approved.",
          "Stage__c": "Decision",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/news/notification-2016-06-10-hepatitis-c-treatments/\" target=\"_blank\">Notification letter</a>",
          "Summary__c": "From 1 July 2016 Viekira Pak and Viekira Pak-RBV will be funded in the community and DHB hospitals for the treatment of genotype 1 non advanced hepatitis C with a prescriber restriction limiting access to infectious disease specialists, gastroenterologists and hepatologists.    This prescriber restriction will be lifted on 1 October 2016, meaning that any relevant prescriber will be able to access full funding for those products from that date",
          "Formatted_Date__c": "Jun 2016",
          "Status_History__c": "a132P000000Ar9hQAC"
        },
        "change": null
      }
    ],
    "dateString": "Jun 2016",
    "collapsed": false,
    "checked": true
  }
]